Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 43, 2013 - Issue 5
1,324
Views
61
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer

, , , , , , , , & show all
Pages 443-453 | Received 14 Aug 2012, Accepted 25 Sep 2012, Published online: 16 Nov 2012

References

  • Carmeliet P, Jain RK. (2000). Angiogenesis in cancer and other diseases. Nature 407:249–257.
  • Chao C, Al-Saleem T, Brooks JJ, Rogatko A, Kraybill WG, Eisenberg B. (2001). Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann Surg Oncol 8:260–267.
  • CHMP assessment report for Votrient, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001141/WC500094275.pdf. 10 October 2012.
  • Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095.
  • GlaxoSmithKline (revised, 2012) Votrient (pazopanib). Prescribing information. GlaxoSmithKline, Research Triangle Park, NC 27709.
  • Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L. (2009). Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220–4227.
  • Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M. (2007). Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6:2012–2021.
  • Pakos EE, Goussia AC, Tsekeris PG, Papachristou DJ, Stefanou D, Agnantis NJ. (2005). Expression of vascular endothelial growth factor and its receptor, KDR/Flk-1, in soft tissue sarcomas. Anticancer Res 25:3591–3596.
  • Sonpavde G, Hutson TE, Sternberg CN. (2008). Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs 17:253–261.
  • Wang J, Coltrera MD, Gown AM. (1994). Cell proliferation in human soft tissue tumors correlates with platelet-derived growth factor B chain expression: an immunohistochemical and in situ hybridization study. Cancer Res 54:560–564.
  • Yudoh K, Kanamori M, Ohmori K, Yasuda T, Aoki M, Kimura T. (2001). Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 84:1610–1615.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.